Nordic Life Science asked Lars Hedbys, CEO of Idogen, about the potential and challenges for cell therapies. For gene and cell therapies 2017 really was a breakthrough year. For example, there was an increasing interest in companies developing these therapies, like the recent news about Takeda’s intention to acquire TiGenix, a biopharma company developing novel stem … Continue reading Important progress for cell therapy